Psychiatric management of the hepatitis C patients

Current Treatment Options in Gastroenterology

Volumn 9, Issue 6, 2006, Pages 508-519

  Rifai, Muhamad Aly ^a   Indest, David ^b   Loftis, Jennifer ^b   Hauser, Peter ^b  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; DISULFIRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM CARBONATE; MIRTAZAPINE; NALTREXONE; NEFAZODONE; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; QUETIAPINE; RIBAVIRIN; RISPERIDONE; SERTRALINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

AGRANULOCYTOSIS; ALCOHOLISM; ANEMIA; ANHEDONIA; ANXIETY DISORDER; APATHY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONCENTRATION LOSS; CONFUSION; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERSOMNIA; IRRITABILITY; LIVER TOXICITY; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; MENTAL DISEASE; MENTAL HEALTH CARE; METABOLIC DISORDER; MOOD DISORDER; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PATIENT ASSESSMENT; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; PREVALENCE; PRIMARY PREVENTION; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR RETARDATION; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RETINA HEMORRHAGE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SEIZURE; SIDE EFFECT; SOCIAL SECURITY; STEVENS JOHNSON SYNDROME; SUBSTANCE ABUSE; THYROID DISEASE; URINARY EXCRETION;

EID: 33751309417     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-006-0007-6     Document Type: Review

References (63)

1. Strader D, Wright T, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004, 39:1147-1171.
2. Armstrong GL, Wasley A, Simard EP, et al.: The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
3. Forton DM, Taylor-Robinson SD, Thomas HC: Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003, 10:81-86.
4. Forton DM, Thomas HC, Taylor-Robinson SD: Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis 2004, 19:383-391.
5. Forton DM, Allsop JM, Main J, et al.: Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001, 358:38-39.
6. Forton DM, Wright M, Knapp S, et al.: New insights into hepatitis C. Clin Med 2002, 2:554-559.
7. Herrine SK: Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002, 136:747-757.
8. Yovtcheva SP, Rifai MA, Motes JK, Van der Linden BJ: Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics 2001, 42:411-415.
9. el-Serag HB, Kunik M, Richardson P, Rabeneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002, 123:476-482.
10. Lehman CL, Cheung RC: Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002, 97:2640-2646.
11. Regier DA, Narrow WE, Rae DS, et al.: The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993, 50:85-94.
12. Norquist GS, Regier DA: The epidemiology of psychiatric disorders and the de facto mental health care system. Annu Rev Med 1996, 47:473-479.
13. Rifai MA, Rosestein DL: Hepatitis C and psychiatry. Focus 2005, 3:194-202.
14. Osher FC, Goldberg RW, McNary SW, et al.: Blood-borne infections and persons with mental illness: substance abuse and the transmission of hepatitis C among persons with severe mental illness. Psychiatr Serv 2003, 54:842-847.
15. Dinwiddie SH, Shicker L, Newman T: Prevalence of hepatitis C among psychiatric patients in the public sector. Am J Psychiatry 2003, 160:172-174.
16. Al Jurdi RK, Burruss JW: Prevalence of hepatitis C in psychiatric institutions. Psychosomatics 2003, 44:439-440.
17. Falck-Ytter Y, Kale H, Mullen KD, et al.: Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002, 136:288-292.
18. Cawthorne CH, Rudat KR, Burton MS, et al.: Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 2002, 97:149-155.
19. Rifai MA, Moles JK, Lehman LP, Van der Linden BJ: Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics 2006, 47:112-121.
20. Rifai MA, Loftis JM, Hauser P: Hepatitis C treatment of veterans with psychiatric illness. Am J Gastroenterol 2006, 101:673-674. Author reply 674-675.
21. Huckans MS, Blackwell AD, Harms TA, Hauser P: Management of hepatitis C disease among VA patients with schizophrenia and substance use disorders. Psychiatr Serv 2006, 57:403-406.
22. Rifai MA, Rosestein DL: Interferon treatment of hepatitis C patients with psychiatric disorders: evidence-based, risk-benefit assessment. Psychosomatics 2005, 46:165-166.
23. Rifai MA, Bozorg B, Rosenstein DL: Interferon for hepatitis C patients with psychiatric disorders. Am J Psychiatry 2004, 161:2331-2332.
24. Chou R, Clark EC, Helfand M: Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004, 140:465-479.
25. Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003, 9:93-110.
26. Rifai MA, Loftis JM, Hauser P: Interferon-alpha treatment of patients with hepatitis C: the role of a comprehensive risk-benefit assessment. CNS Drugs 2005, 19:719-721. Author reply 721-722.
27. Crone CC, Gabriel GM, Wise TN: Managing the neuropsychiatric side effects of interferon-based therapy for hepatitis C. Cleve Clin J Med 2004, 71 (Suppl 3):S27-S32.
28. Loftis JM, Hauser P: The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190.
29. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
30. Fried MW: Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5 SuppL 1):S237-S244.
31. Hadziyannis SJ, Sette IL Jr, Morgan TR, et al.: Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
32. Paynard T, Yuen MF, Ratziu V, Lung Lai C: Viral hepatitis C. Lancet 2003, 362:2095-2100.
33. Geppert CM, Dettmer E, Jakiche A: Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics 2005, 46:392-401.
34. Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health 2000, 90:1562-1569.
35. Rifai MA, Moles JK, Van der Linden BJ: Hepatitis C and post-traumatic stress disorder in US veterans. Am J Gastroenterol 2003, 98(9 SUPPl 1):S99-S100.
36. Maunder RG, Hunter JJ, Feinman SV. Interferon treatment of hepatitis C associated with symptoms of PTSD. Psychosomatics 1998, 39:461-464.
37. Sylvestre DL: Approaching treatment for hepatitis C virus infection in substance users. Clin Infect Dis 2005, 41(Suppl 1):S79-S82.
38. Sylvestre DL, Loftis JM, Hauser P, et al.: Co-occurring hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care. J Urban Health 2004, 81:719-734.
39. Safdar K, Schiff ER: Alcohol and hepatitis C. Semin Liver Dis 2004, 24:305-315.
40. Fireman M, Indest DW, Blackwell A, et al.: Addressing trimorbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 2005, 40(Suppl 5):S286-S291.
41. Manns M, McHutchison J, Gordon S, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
42. Hauser P, Khosla J, Aurora H, et al.: A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry 2002, 7:942-947.
43. Wichers MC, Kock GH, Robaeys G, et al.: IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005, 10:538-544.
44. Capuron L, Gumnick JF, Musselman DL, et al.: Neuro-behavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
45. Capuron L, Miller AH: Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56:819-824.
46. McHutchison JG, Marms M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061-1069.
47. Kraus MR, Schafer A, Csef H, Scheurien M: Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005, 11:1769-1774.
48. Dieperink E, Willenbring M, Ho S: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157: 867-876.
49. Jonasch E, Kumar UN, Linette GP, et al.: Adjuvant highdose interferon alfa-2b in patients with high-risk melanoma. Cancer J 2000, 6:139-145.
50. Hauser P, Loftis JM, Dieperink EW, et al.: Depression and substance use disorders in chronic hepatitis C: implications of new guidelines and experience in the VA health care system. Fed Pract 2004, 21:90-102.
51. Loftis IM, Hauser P: Hepatitis C in patients with psychiatric disease and substance abuse: screening strategies and co-management models of care. Curr Hepat Rep 2003, 2:93-100.
52. Loftis JM, Hauser P: Co-management of depression and HCV treatment. Psychiatr Ann 2003, 33:385-391.
53. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997, 26(3 Suppl 1):2S-10S.
54. Musselman DL, Lawson DH, Gumnick JF, et al.: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
55. Horikawa N, Yamazaki T, Izumi N, Uchihara M: Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psychiatry 2003, 25:34-38.
56. Raison CL, Borisov AS, Broadwell SD, et al.: Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005, 66:41-48.
57. Kraus MR, Schafer A, Al-Taie O, Scheurlen M: Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005, 12:96-100.
58. Loftis JM, Hauser P: The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190.
59. Schramm T, Lawford B, Macdonald G, Cooksley W: Sertraline treatment of inteyferon-alfa-induced depressive disorder. Med J Aust 2000, 173:359-361.
60. Kraus MR, Schafer A, Faller H, et al.: Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002, 16:1091-1099.
61. Dieperink E,Ho SB,Thuras P, Willenbring ML: A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
62. Hauser P, Soler R, Reed S, et al.: Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000, 41:439-441.
63. el-Serag HB, Kunik M, Richardson P, Rabeneck L: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002, 123:476-482.